Holiday Sale — Get 40% off Vantage for yourself or as a gift

Published 7 months ago • loading... • Updated 7 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Summary by Weatherford Democrat

BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released pharmacokinetic and metabolism data from its Phase 1…

2 Articles

2 Articles

milescitystar.com

Reposted by

Weatherford Democrat

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released pharmacokinetic and metabolism data from its Phase 1…

7 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left2Leaning Right0Center0Last Updated7 months agoBias Distribution

100% Left

Bias Distribution

100% of the sources lean Left

100% Left

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Weatherford Democrat broke the news in 7 months ago on Tuesday, May 6, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics